Use the collections feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Marcus Harbord, Vito Annese, Stephan R Vavricka, Matthieu Allez, Manuel Barreiro-de Acosta, Kirsten Muri Boberg, Johan Burisch, Martine De Vos, Anne-Marie De Vries, Andrew D Dick, Pascal Juillerat, Tom H Karlsen, Ioannis Koutroubakis, Peter L Lakatos, Tim Orchard, Pavol Papay, Tim Raine, Max Reinshagen, Diamant Thaci, Herbert Tilg, Franck Carbonnel
No abstract text is available yet for this article.
March 2016: Journal of Crohn's & Colitis
#2
RANDOMIZED CONTROLLED TRIAL
Jean Frédéric Colombel, William J Sandborn, Walter Reinisch, Gerassimos J Mantzaris, Asher Kornbluth, Daniel Rachmilewitz, Simon Lichtiger, Geert D'Haens, Robert H Diamond, Delma L Broussard, Kezhen L Tang, C Janneke van der Woude, Paul Rutgeerts
BACKGROUND: The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease are unknown. METHODS: In this randomized, double-blind trial, we evaluated the efficacy of infliximab monotherapy, azathioprine monotherapy, and the two drugs combined in 508 adults with moderate-to-severe Crohn's disease who had not undergone previous immunosuppressive or biologic therapy. Patients were randomly assigned to receive an intravenous infusion of 5 mg of infliximab per kilogram of body weight at weeks 0, 2, and 6 and then every 8 weeks plus daily oral placebo capsules; 2...
April 15, 2010: New England Journal of Medicine
1
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
